Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
Conference Posters and Presentations
2022 SfN Poster: 374.18 Exploring SARM1 Inhibition in Mouse Models of CMT (1)

2022 SfN Poster: 374.18 Exploring SARM1 Inhibition in Mouse Models of CMT (1)

Published Date November 14, 2022

Previous Flipbook

2022 ASH Poster: In Vivo PBMC Humanized Mouse Model to Assess Individual Variability in Efficacy and Toxicology
Next Flipbook

2022 PEGS EU Immune System-Humanized Mouse Models to Predict Outcomes of Human-Specific Immuno-Modulatory Therapies

Most Recent Flipbooks

20 days ago
Poster: Translational Humanized Models for Immunotherapy Drug Development | CHI 2024

Read Flipbook
20 days ago
Poster: Translational Humanized Models for Immunotherapy Drug Development | Immuno 2024

Read Flipbook
20 days ago
Poster: Evaluating toxicity and efficacy of bispecific EGFRXCD3 T cell engager in solid tumor-bearing humanized animal model

Read Flipbook
20 days ago
Poster: Assessing impacts of tumor burden and CAR-T cell dosage on the toxicity and efficacy profile of CD19 CAR-T therapy in a PBMC Model

Read Flipbook
20 days ago
Poster: Modeling individual variability in CD19 CAR-T therapy - An in vivo study with PBMC-humanized mice

Read Flipbook
20 days ago
Poster: The NSG-Flt3KO; Tg(hFLT3LG) hIL15 mouse strain improves engraftment of innate immune cells post-CD34+ humanization

Read Flipbook
20 days ago
Poster: Establishing orthotopic renal cell carcinoma xenograft in PBMC-humanized immunodeficient NSG-MHC I:II double knock-out mice

Read Flipbook
20 days ago
Poster: Hu-mouse model to assess PBMC donor derived autologous CD19 CAR-Ts for efficacy against Raji tumors and related Cytokine Release

Read Flipbook
6 months ago
SITC 2023 Comparison of Blinatumomab and Biosimilar CD19xCD3 BiTE responses in PBMC-Humanized Mice Used as a Preclinical Lymphoma Mouse Mode

Read Flipbook
6 months ago
SITC 2023 PBMC Humanized Mouse Model with Clinical Relevance in Assessing the Safety Profile of 4-1BB Agonist, Urelumab, in 5 Donors

Read Flipbook
6 months ago
PEGS EU 2023 - A Novel, Translational Platform to Assess the Efficacy and Toxicity of Bispecific Antibodies

Read Flipbook
6 months ago
PEGS EU 2023 - Predicting the Clinical PK of Candidate Therapeutic Antibodies

Read Flipbook
6 months ago
PEGS EU 2023 - Translational Humanized Models for Immunotherapy Drug Development

Read Flipbook
7 months ago
2023 AALAS P403 Comparing tumor erosion rate following P16MC38 subcutaneous (SC) vs. mammary fat pad (MFP) injections

Read Flipbook
7 months ago
2023 AALAS P402 Evaluating sub-renal capsule cavity tumor growth in immunodeficient NSG-MHC I/II double knock-out mice

Read Flipbook
about 1 year ago
2023 AACR The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics

Read Flipbook
about 1 year ago
2023 AACR Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized m

Read Flipbook
about 1 year ago
2023 AACR A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodi

Read Flipbook
about 1 year ago
2023 AACR Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoi

Read Flipbook
about 1 year ago
2023 AACR Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunother

Read Flipbook

Recommended for you

Return to Home

© The Jackson Laboratory